News
The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback